Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats

Norbert Mencke , Wolfgang Bäumer , Kristine Fraatz , Ralph Krebber , Marc Schneider , Katrin Blazejak
{"title":"Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats","authors":"Norbert Mencke ,&nbsp;Wolfgang Bäumer ,&nbsp;Kristine Fraatz ,&nbsp;Ralph Krebber ,&nbsp;Marc Schneider ,&nbsp;Katrin Blazejak","doi":"10.1016/j.crpvbd.2023.100126","DOIUrl":null,"url":null,"abstract":"<div><p>Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a T<sub>max</sub> of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared <em>via</em> the faeces (54% within 28 days), renal clearance was neglectable (&lt; 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks.</p></div>","PeriodicalId":94311,"journal":{"name":"Current research in parasitology & vector-borne diseases","volume":"4 ","pages":"Article 100126"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current research in parasitology & vector-borne diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667114X23000146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ​ml/kg to cats, tigolaner reached mean peak concentrations of 1352 ​μg/l with a Tmax of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 ​l/kg and plasma clearance was low with 0.005 ​l/h/kg. Overall plasma exposure was 1566 ​mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 ​μg/l and 48 ​μg/l (reached after 1.5 days and 5 ​h, respectively). Overall plasma exposures were 20.6 and 3.69 ​mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部给药组合产品(Felpreva®)和单独活性成分静脉给药后替戈兰那、emodepside和吡喹酮在猫体内的血浆药代动力学
猫用Felpreva®含有新的杀螨/杀虫活性成分替戈兰,分别与杀线虫剂和杀螨剂化合物依莫地肽和吡喹酮固定组合。在作为固定组合Felpreva®进行局部(现场)治疗后,对临床健康猫的替戈拉纳、依莫地肽和吡喹酮的血浆药代动力学进行了评估。为了测定生物利用度,还进行了单一活性成分的静脉给药。使用0.148的目标剂量体积单次局部给药Felpreva®后​对猫来说,替戈拉纳达到了1352的平均峰值浓度​μg/l,Tmax为12天,平均半衰期为24天。模拟每91天重复局部给药表明,在两到三次给药内达到稳定状态后,积聚的风险很低。静脉给药后计算的分布体积为4​l/kg,血浆清除率低至0.005​l/h/kg。总的血浆暴露量为1566​局部给药后,提供57%的绝对生物利用度。提戈拉纳主要通过粪便清除(28天内清除54%),肾脏清除率可忽略不计(28天以内<0.5%)。埃莫迪肽和吡喹酮的平均峰值浓度为44​μg/l和48​μg/l(1.5天后和5天后达到​h、 分别)。总体血浆暴露量分别为20.6和3.69​毫克*小时/升。局部给药后,依莫司肽和吡喹酮的消除半衰期分别为14.5天和10天。使用2.5倍和5倍剂量倍数局部给药Felpreva®后,观察到所有三种活性成分的血浆暴露量几乎成比例增加。通过添加替戈拉纳,Felpreva®结合了Profender®斑点猫中所含的依莫司肽和吡喹酮的既定药代动力学(PK)特征,以及适用于3个月防跳蚤和蜱虫的替戈拉内的良好PK。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
0
期刊最新文献
Larvicidal activity of Bacillus thuringiensis strains against Aedes aegypti and Culex quinquefasciatus mosquitoes Genetic diversity of Plasmodium vivax and Plasmodium falciparum field isolates from Honduras in the malaria elimination phase Redefining Rhipicephalus sanguineus (sensu lato) species complex in Greece focusing on the mitogenome of Rhipicephalus secundus DNA-elucidated life cycle of a highly pathogenic avian nematode: Streptocara incognita (Spirurida: Acuariidae) and its morphological development from infective third-stage larva to adult Small mammals as hosts of vector-borne pathogens in the High Tatra Mountains region in Slovakia, Central Europe
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1